Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL)

Barclays PLC bought a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,107 shares of the company's stock, valued at approximately $429,000. Barclays PLC owned about 0.07% of Grail at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. FNY Investment Advisers LLC purchased a new position in Grail in the 4th quarter valued at $26,000. Lindbrook Capital LLC acquired a new stake in shares of Grail in the 4th quarter worth $28,000. Sterling Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at about $29,000. Wellington Shields Capital Management LLC acquired a new position in shares of Grail during the fourth quarter worth about $33,000. Finally, New York State Common Retirement Fund purchased a new position in Grail during the fourth quarter worth about $59,000.

Grail Stock Down 23.3%

GRAL stock traded down $10.00 during trading on Wednesday, reaching $32.89. 5,119,519 shares of the company were exchanged, compared to its average volume of 1,247,650. The stock's 50 day moving average price is $29.69 and its 200 day moving average price is $26.15. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.93. The company had revenue of $31.84 million for the quarter, compared to analyst estimates of $35.80 million. On average, research analysts expect that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GRAL shares. Canaccord Genuity Group lifted their price objective on Grail from $32.00 to $43.00 and gave the company a "buy" rating in a report on Wednesday. Morgan Stanley raised their price target on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th.

Insider Activity

In other news, President Joshua J. Ofman sold 2,109 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the transaction, the president now owns 559,673 shares of the company's stock, valued at $17,461,797.60. The trade was a 0.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares in the company, valued at $10,457,304. The trade was a 0.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 194,948 shares of company stock worth $6,583,130 over the last three months. 1.85% of the stock is currently owned by corporate insiders.

Grail Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.